The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2025 | Switching from cetuximab to panitumumab in BRAF V600E mCRC
Annalice Gandini, MD, San Martino University Hospital of Genoa, Genoa, Italy, discusses an international multicenter analysis from the AGEO group assessing outcomes of patients with BRAF V600E mutated metastatic colorectal cancer (mCRC), who discontinued encorafenib-cetuximab due to infusion-related reactions and switched to encorafenib-panitumumab. Panitumumab maintained efficacy with encouraging disease control and was generally well tolerated, with adverse events mostly low grade and no further infusion-related reactions reported. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, this is a study, a real-world study that I have conducted when I spent a research fellowship period at the hospital Pompidou in Paris. And so this study was evaluating safety and efficacy of the combination of encorafenib plus panitumumab after a toxicity during encorafenib cetuximab treatment so we’re focusing on metastatic colorectal cancer harboring a BRAF V600E mutation and we collected 20 patients in total after a proposition of collaboration program in different countries so we have patients from Germany, Italy, US and France and the population is a real world population so characteristics are in line with the patient that we know with metastatic colorectal cancer...
Yes, this is a study, a real-world study that I have conducted when I spent a research fellowship period at the hospital Pompidou in Paris. And so this study was evaluating safety and efficacy of the combination of encorafenib plus panitumumab after a toxicity during encorafenib cetuximab treatment so we’re focusing on metastatic colorectal cancer harboring a BRAF V600E mutation and we collected 20 patients in total after a proposition of collaboration program in different countries so we have patients from Germany, Italy, US and France and the population is a real world population so characteristics are in line with the patient that we know with metastatic colorectal cancer. Most of the patients were treated in second line and 19 out of 20 switched from cetuximab to panitumumab after a severe infusion-related reaction. One patient out of 20 was treated directly with encorafenib panitumumab. What we saw was that the results with the combination of encorafenib panitumumab were similar to the known results with encorafenib that came from the BEACON trial. So we had an objective response rate of 25%, a disease control rate of 75%, and a median PFS of 6.2 months and a median OS of 11 months. So we saw that this combination is similarly effective. And in terms of toxicity, we do not have an infusion-related reaction with panitumumab, and we have a normal and known toxicity with anti-EGFR treatments, especially skin rash, asthenia and alteration of the laboratory blood test.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
